Search
Research
Informing rubella vaccination strategies in East Java, Indonesia through transmission modellingA single dose of rubella vaccine will take longer to reduce the burden of rubella and will be less robust to lower vaccine coverage
Research
Pertussis Disease and Antenatal Vaccine Effectiveness in Australian ChildrenPopulation-level studies of severe pertussis extending beyond infancy are sparse, and none in the context of antenatal vaccination. We compared hospitalized pertussis cases from birth to 15 years of age before and after introduction of antenatal immunization.
Research
Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot studyThe P3-MumBubVax intervention is feasible and acceptable in the Australian public antenatal setting
Research
Safety of live attenuated herpes zoster vaccine in adults 70–79 years: A self-controlled case series analysis using primary care dataNo new safety concerns were identified for live attenuated herpes zoster vaccine in this study based on a novel, Australian primary care data source
Research
The ORVAC trial: A clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritisWe hypothesised that scheduling an additional (third) dose of oral human rotavirus vaccine for children aged 6 to <12 months would improve protection
Research
Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical ResearchWe outline three scenarios from across the health spectrum where issues with health informatics are exemplified.
Research
Paediatric antimicrobial stewardship and safe prescribing: An assessment of medical staff knowledge and behaviourParticipants demonstrated a good understanding of safe prescribing and antimicrobial stewardship
Research
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World PerspectiveThis review supports the recommended use of palivizumab for reducing RSV-associated hospitalisation rates in premature babies born at gestational age <33 weeks.
Research
Determinants of incomplete vaccination and non-vaccination among WA childrenTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.